Skip to main content

Table 4 Body composition values at baseline (BL) and week-12 (W12)

From: A pilot study of brisk walking in sedentary combination antiretroviral treatment (cART)- treated patients: benefit on soluble and cell inflammatory markers

  All Walk Strength-Walk
BL W12 p BL W12 p BL W12 p
Anthropometrics
 Weight (kg) 75.0 (65.0-79.0) 72.5 (63.3-77.8) 0.0003 74.0 (62.0-78.5) 71.0 (60–77) 0.0001 76.0 (71.0-81.0) 75.0 (71.5-79.5) n.s.
 BMI (kg/m2) 25.6 (22.2-27.2) 25.0 (21.5 -26.9) 0.004 25.3 (21.6-27.5) 24.9 (21.2-27.0) 0.001 25.8 (24.1-26.9) 25.0 (23.9-27.0) n.s.
 Waist Circumference (cm) 93 (86–102) 92 (84–99) 0.050 93 (82–102) 92 (83–100) 0.046 94 (88–100) 92 (88–98) n.s.
 Hip Circumference (cm) 95 (91–99) 94 (90–98) 0.040 97 (92–100) 95 (90–100) n.s. 92 (91–99) 92 (89–97) n.s.
 Leg Circumference (cm) 53 (49–57) 53 (49–56) n.s. 53 (47–56) 52 (48–55) n.s. 53 (51–58) 53 (50–57) n.s.
 Waist-to-hip ratio 0.98 (0.92-0.95) 0.98 (0.95-1.03) n.s. 0.96 (0.90-0.93) 0.96 (0.93-1.00) n.s. 1.03 (1.01-1.03) 1.02 (1.00-1.05) n.s.
DEXA
 Total Fat (Kg) 17.74 (12.52-22.85) 17.66 (9.28-22.41) n.s. 20.73 (10.07-27.79) 21.48 (9.44-28.94) n.s. 17.58 (16.16-19.19) 17.52 (10.20-18.38) n.s.
 Total Lean (Kg) 50.88 (47.06-58.23) 52.64 (46.38-57.90) n.s. 49.52 (38.27-57.55) 48.43 (38.19-57.25) n.s. 58.22 (50.86-58.24) 57.84 (52.66-59.93) n.s.
 Total BMC (Kg) 2.60 (2.38-2 95) 2.59 (2.35-2.93) n.s. 2.49 (2.01-2.91) 2.55 (2.30-2.91) n.s. 2.82 (2.51-3.08) 2.85 (2.48-3.02) n.s.
 Total BMD 1.15 (1.06-1.21) 1.15 (1.06-1.22) n.s. 1.14 (1.05-1.2) 1.13 (1.03-1.21) n.s. 1.20 (1.13-1.20) 1.19 (1.07-1.23) n.s.
 Total Fat (%) 25.6 (21.5-33.3) 25.8 (16.7-32.2) n.s. 28.1 (20.1-37.4) 26.9 (16.7-37.2) n.s. 24.0 (22.3-27.1) 23.2 (16.5-26.4) n.s.
  1. Values are expressed as median (Q1-Q3). W12 values were compared to BL values by the Wilcoxon matched-pairs signed rank test
  2. BMI body mass index, DEXA Dual-energy X-ray absorptiometry, BMC body mineral content, BMD bone mineral density